Reduced migratory capacity, inhibitedIL-12 cytokine production, inadequate Th1 and CD8+ T-cell response, and presumed generationof IL-10-producing tolerogenic DC could influence the outcome of DC-based vaccinationtherapies against cancer. Here, CD8A is linked to cancer.